Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Wang X, Xu Y, Scott DE, Murata H, Struble EB. Binding and neutralizing anti-cytomegalovirus activities in immune globulin products. Biologicals 2017;50:35-41. [PMID: 29029807 DOI: 10.1016/j.biologicals.2017.09.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Revised: 07/20/2017] [Accepted: 09/18/2017] [Indexed: 01/02/2023] Open

For:	Wang X, Xu Y, Scott DE, Murata H, Struble EB. Binding and neutralizing anti-cytomegalovirus activities in immune globulin products. Biologicals 2017;50:35-41. [PMID: 29029807 DOI: 10.1016/j.biologicals.2017.09.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Revised: 07/20/2017] [Accepted: 09/18/2017] [Indexed: 01/02/2023] Open

Number

Cited by Other Article(s)

Mizrahi RA, Lin WY, Gras A, Niedecken AR, Wagner EK, Keating SM, Ikon N, Manickam VA, Asensio MA, Leong J, Medina-Cucurella AV, Benzie E, Carter KP, Chiang Y, Edgar RC, Leong R, Lim YW, Simons JF, Spindler MJ, Stadtmiller K, Wayham N, Büscher D, Terencio JV, Germanio CD, Chamow SM, Olson C, Pino PA, Park JG, Hicks A, Ye C, Garcia-Vilanova A, Martinez-Sobrido L, Torrelles JB, Johnson DS, Adler AS. GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2. Pathogens 2022;11:806. [PMID: 35890050 PMCID: PMC9320065 DOI: 10.3390/pathogens11070806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 07/13/2022] [Accepted: 07/15/2022] [Indexed: 11/16/2022] Open

Abstract

Conventionally, hyperimmune globulin drugs manufactured from pooled immunoglobulins from vaccinated or convalescent donors have been used in treating infections where no treatment is available. This is especially important where multi-epitope neutralization is required to prevent the development of immune-evading viral mutants that can emerge upon treatment with monoclonal antibodies. Using microfluidics, flow sorting, and a targeted integration cell line, a first-in-class recombinant hyperimmune globulin therapeutic against SARS-CoV-2 (GIGA-2050) was generated. Using processes similar to conventional monoclonal antibody manufacturing, GIGA-2050, comprising 12,500 antibodies, was scaled-up for clinical manufacturing and multiple development/tox lots were assessed for consistency. Antibody sequence diversity, cell growth, productivity, and product quality were assessed across different manufacturing sites and production scales. GIGA-2050 was purified and tested for good laboratory procedures (GLP) toxicology, pharmacokinetics, and in vivo efficacy against natural SARS-CoV-2 infection in mice. The GIGA-2050 master cell bank was highly stable, producing material at consistent yield and product quality up to >70 generations. Good manufacturing practices (GMP) and development batches of GIGA-2050 showed consistent product quality, impurity clearance, potency, and protection in an in vivo efficacy model. Nonhuman primate toxicology and pharmacokinetics studies suggest that GIGA-2050 is safe and has a half-life similar to other recombinant human IgG1 antibodies. These results supported a successful investigational new drug application for GIGA-2050. This study demonstrates that a new class of drugs, recombinant hyperimmune globulins, can be manufactured consistently at the clinical scale and presents a new approach to treating infectious diseases that targets multiple epitopes of a virus.

Collapse

Affiliation(s)

Rena A. Mizrahi GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Wendy Y. Lin Alira Health, Inc., Framingham, MA 01702, USA; (W.Y.L.); (S.M.C.); (C.O.)
Ashley Gras GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Ariel R. Niedecken GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Ellen K. Wagner GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Sheila M. Keating GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Nikita Ikon GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Vishal A. Manickam GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Michael A. Asensio GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Jackson Leong GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Angelica V. Medina-Cucurella GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Emily Benzie GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Kyle P. Carter GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Yao Chiang GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Robert C. Edgar GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Renee Leong GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Yoong Wearn Lim GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Jan Fredrik Simons GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Matthew J. Spindler GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Kacy Stadtmiller GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Nicholas Wayham GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Dirk Büscher Grifols S.A., 08174 Sant Cugat del Vallès, Spain; (D.B.); (J.V.T.)
Jose Vicente Terencio Grifols S.A., 08174 Sant Cugat del Vallès, Spain; (D.B.); (J.V.T.)
Clara Di Germanio Vitalant Research Institute, San Francisco, CA 94118, USA;
Steven M. Chamow Alira Health, Inc., Framingham, MA 01702, USA; (W.Y.L.); (S.M.C.); (C.O.)
Charles Olson Alira Health, Inc., Framingham, MA 01702, USA; (W.Y.L.); (S.M.C.); (C.O.)
Paula A. Pino Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; (P.A.P.); (A.H.); (A.G.-V.); (L.M.-S.); (J.B.T.)
Jun-Gyu Park Disease Intervention and Prevention Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; (J.-G.P.); (C.Y.)
Amberlee Hicks Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; (P.A.P.); (A.H.); (A.G.-V.); (L.M.-S.); (J.B.T.)
Chengjin Ye Disease Intervention and Prevention Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; (J.-G.P.); (C.Y.)
Andreu Garcia-Vilanova Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; (P.A.P.); (A.H.); (A.G.-V.); (L.M.-S.); (J.B.T.)
Luis Martinez-Sobrido Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; (P.A.P.); (A.H.); (A.G.-V.); (L.M.-S.); (J.B.T.) Disease Intervention and Prevention Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; (J.-G.P.); (C.Y.)
Jordi B. Torrelles Population Health Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; (P.A.P.); (A.H.); (A.G.-V.); (L.M.-S.); (J.B.T.) Disease Intervention and Prevention Program, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; (J.-G.P.); (C.Y.)
David S. Johnson GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)
Adam S. Adler GigaGen, Inc., South San Francisco, CA 94080, USA; (R.A.M.); (A.G.); (A.R.N.); (E.K.W.); (S.M.K.); (N.I.); (V.A.M.); (M.A.A.); (J.L.); (A.V.M.-C.); (E.B.); (K.P.C.); (Y.C.); (R.C.E.); (R.L.); (Y.W.L.); (J.F.S.); (M.J.S.); (K.S.); (N.W.); (D.S.J.)

Collapse

Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection. Int J Mol Sci 2021;22:ijms22168728. [PMID: 34445434 PMCID: PMC8395925 DOI: 10.3390/ijms22168728] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 07/29/2021] [Accepted: 07/30/2021] [Indexed: 02/06/2023] Open

Schampera MS, Arellano-Galindo J, Kagan KO, Adler SP, Jahn G, Hamprecht K. Role of pentamer complex-specific and IgG subclass 3 antibodies in HCMV hyperimmunoglobulin and standard intravenous IgG preparations. Med Microbiol Immunol 2018;208:69-80. [PMID: 30203132 DOI: 10.1007/s00430-018-0558-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Accepted: 08/24/2018] [Indexed: 11/24/2022]

Pereira L. Congenital Viral Infection: Traversing the Uterine-Placental Interface. Annu Rev Virol 2018;5:273-299. [PMID: 30048217 DOI: 10.1146/annurev-virology-092917-043236] [Citation(s) in RCA: 100] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]